Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 689.45

-0.9%

10:51 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DewDiligence_on_SI who wrote (2679)	4/8/2019 5:06:44 PM
From: Miljenko Zuanic	of 3557

< (REGN retains primary responsibility for the ophthalmic component of the ALNY deal.)> Any idea/insight what may be target/candidates that complement/substitute Eylea franchise, IF at all wet AMD/DME is targeted disease? For dry-AMD target is different, I guess!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next